Autres langues

28/08 Dawnrays Pharmaceutical Limited Reports Earnings Results for the Half Year Ended June 30, 2026
28/08 Dawnrays Pharmaceutical Limited Announces Interim (Semi-Annual) Dividend for the Six Months Ended 30 June 2026, Payable on 09 October 2026
29/05 Dawnrays Pharmaceutical Limited Announces That the Group's Subsidiary, Fujian Dawnrays Pharmaceutical Co., Ltd. Obtains Approval for Drug Production and Registration for Trazodone Hydrochloride Tablets 50Mg and 100Mg
22/05 Dawnrays Pharmaceutical Limited Approves Final Dividend for the Year Ended 31 December 2025
27/03 Dawnrays Pharmaceutical Limited Reports Earnings Results for the Full Year Ended December 31, 2025
27/03 Dawnrays Pharmaceutical (Holdings) final dividend of HK$0.048 per share
27/03 Dawnrays Pharmaceutical Limited Proposes Final Cash Dividend for the Year Ended December 31, 2025, Payable on June 12, 2026
22/08/25 Dawnrays Pharmaceutical Limited Reports Earnings Results for the Half Year Ended June 30, 2025
22/08/25 Dawnrays Pharmaceutical Limited Announces Interim Dividend for the Six Months Ended 30 June 2025, Payable on 03 October 2025
22/08/25 Dawnrays pharmaceutical reports HY net income attributable of RMB104.6 mln
31/07/25 Dawnrays Pharmaceutical Limited Announces Appointment of Hu Shuo as Non-Executive Director with Effect from 1 August 2025
23/05/25 Dawnrays Pharmaceutical Limited Declares Final Dividend for the Year Ended 31 December 2024
23/05/25 Dawnrays Pharmaceutical Limited Declares Special Dividend for the Year Ended 31 December 2024
28/03/25 Dawnrays Pharmaceutical (Holdings) Posts FY Profit Attributable Of Rmb564.9 Million
28/03/25 Dawnrays Pharmaceutical Limited Proposes Special Dividend for the Year Ended December 31, 2024, Payable on 12 June 2025
28/03/25 Dawnrays Pharmaceutical Limited Proposes Final Ordinary Dividend for the Year Ended December 31, 2024, Payable on 12 June 2025
28/03/25 Dawnrays Pharmaceutical Limited Reports Earnings Results for the Full Year Ended December 31, 2024
03/10/24 Dawnrays Pharmaceutical Grants 16 Million Share Options to CEO, Employees
16/09/24 Dawnrays Pharmaceutical Appoints CEO
13/09/24 Dawnrays Pharmaceutical Limited Appoints Yu Liwei as Chief Executive Officer
11/09/24 Dawnrays Pharmaceutical's CEO Resigns
11/09/24 Dawnrays Pharmaceutical Limited Announces Resignation of Wu Weixian as Chief Executive Officer
26/08/24 Dawnrays Pharmaceutical H1 Profit Spikes; Shares Up 3%
23/08/24 Dawnrays Pharmaceutical Limited Announces Interim Dividend for the Six Months Ended 30 June 2024, Payable on 03 October 2024, Payable on 03 October 2024
23/08/24 Dawnrays Pharmaceutical Limited Reports Earnings Results for the Half Year Ended June 30, 2024
Aucun résultat pour cette recherche